SCHEMBL20406660

SCHEMBL20406660

CCOC(=O)C(F)(F)c1ncc(O)cc1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ GAA P10253 2/20 0.37
▸ POLB P06746 2/20 0.37
▸ HPGD P15428 1/20 0.37
▸ CA12 O43570 2/20 0.37
▸ CA1 P00915 2/20 0.37
▸ CA2 P00918 2/20 0.37
▸ CA7 P43166 2/20 0.37
▸ CA9 Q16790 2/20 0.37
▸ CA14 Q9ULX7 2/20 0.37
▸ L3MBTL1 Q9Y468 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ NR1H2 P55055 1/20 0.36
▸ NR1H3 Q13133 1/20 0.36
▸ MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20271640 0.80 KDM4E (0.41) KDM4EL3MBTL1ALDH1A1MEN1KMT2A
SCHEMBL17315789 0.78 KDM4E (0.38) SMN1; SMN2KDM4EGAAPOLBL3MBTL1
SCHEMBL17315815 0.78 KDM4E (0.38) CYP3A4SMN1; SMN2KDM4EGAAPOLB
SCHEMBL15999650 0.77 L3MBTL1 (0.41) CYP3A4SMN1; SMN2KDM4EGAAPOLB
SCHEMBL14932583 0.77 L3MBTL1 (0.41) CYP3A4SMN1; SMN2KDM4EHPGDL3MBTL1
SCHEMBL17420749 0.76 MAPT (0.44) CYP3A4SMN1; SMN2KDM4EGAAPOLB
SCHEMBL20406093 0.76 KMT2A (0.41) SMN1; SMN2KDM4EGAAPOLBHPGD
SCHEMBL17622561 0.75 KDM4E (0.39) SMN1; SMN2KDM4EGAAPOLBHPGD
SCHEMBL17315810 0.75 L3MBTL1 (0.46) SMN1; SMN2KDM4EGAAPOLBHPGD
SCHEMBL17315802 0.75 S1PR1 (0.41) CYP3A4KDM4EHPGDL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10647675-B2 Biaryl derivative and medicine containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2020-05-12 — — US disclosed
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2019-02-21 — — US disclosed
EP-3351533-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME Kaken Pharmaceutical Co., Ltd. (JP) 2018-07-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647675-B2 Biaryl derivative and medicine containing same MAN2B1, CBR3, MANBA CYP3A4 224/4885SMN1; SMN2 4801/4885TDP1 4417/4885
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME MAN2B1, CBR3, MANBA CYP3A4 224/4885SMN1; SMN2 4801/4885TDP1 4417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback